Fidelis Capital Partners LLC Has $979,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Fidelis Capital Partners LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 49.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,960 shares of the company’s stock after acquiring an additional 1,634 shares during the period. Fidelis Capital Partners LLC’s holdings in Zoetis were worth $979,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Blue Bell Private Wealth Management LLC lifted its stake in shares of Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its stake in Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 112 shares during the period. VitalStone Financial LLC bought a new position in Zoetis during the first quarter worth about $37,000. Evermay Wealth Management LLC grew its position in shares of Zoetis by 439.3% during the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the period. Finally, Worth Asset Management LLC acquired a new position in shares of Zoetis during the 1st quarter worth about $26,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 2,209 shares of company stock worth $371,293 in the last three months. Insiders own 0.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a report on Tuesday. Stifel Nicolaus dropped their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. Barclays lifted their target price on Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, February 14th. Finally, The Goldman Sachs Group increased their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $221.75.

Zoetis Stock Up 1.1 %

Shares of ZTS stock traded up $1.60 on Thursday, hitting $153.11. 4,729,796 shares of the stock were exchanged, compared to its average volume of 2,989,420. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The firm has a market capitalization of $70.03 billion, a P/E ratio of 30.15, a price-to-earnings-growth ratio of 2.34 and a beta of 0.85. Zoetis Inc. has a fifty-two week low of $148.48 and a fifty-two week high of $201.92. The business has a 50-day moving average of $177.35 and a 200 day moving average of $180.39.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company’s revenue was up 8.5% compared to the same quarter last year. During the same period last year, the company earned $1.15 EPS. Equities analysts anticipate that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.13%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.